Trial Profile
An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit [EXTENSION OF 700201796]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Grass SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
- Focus Therapeutic Use
- Sponsors Niox
- 27 Sep 2019 Results assessing efficacy and safety of grass allergen peptides published in the Journal of Allergy and Clinical Immunology
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2013 New trial record